WCLC 2025 has numerous topics on ADCs, and in the spirit of learning, I am joining the discussion. Let’s see how ADCs are viewed in the field of lung cancer, a leading area in cancer treatment, and what research directions exist for ADCs in this domain.Biomarkers for ADCs: IHC and Beyond, presented by Dr. Sewanti … Read more
Accurate diagnosis and staging of breast cancer are crucial for guiding clinical treatment strategies and predicting patient survival outcomes. Current clinical methods face limitations in detecting small tumors and micrometastases, such as imaging techniques; although biopsy remains the gold standard, its invasiveness makes it unsuitable for repeated use. Liquid biopsy is a promising solution that … Read more
Let’s take a look at the recent hot topic of ADC drugs, and systematically learn about the review published in CancersAntibody–Drug Conjugates for the Treatment of Breast Cancer. Abstract Currently, besides endocrine therapy and targeted drugs, metastatic breast cancer (BC) commonly uses chemotherapy as a treatment method. However, the lack of tumor specificity and toxicity … Read more
IntroductionIn the field of breast cancer treatment, antibody-drug conjugates (ADC) are gradually becoming an important therapeutic approach.ADC drugs are a new type of cancer treatment that combines the targeting capability of antibodies with the potent killing power of chemotherapy drugs, allowing for precise delivery of chemotherapy agents to cancer cells, thereby improving efficacy and reducing … Read more
With the recent approvals of Trastuzumab emtansine (T-DM1) and Gemtuzumab ozogamicin in China, the review of Trastuzumab deruxtecan (T-DXd, DS-8201) is progressing steadily, marking the arrival of a “future” where antibody-drug conjugates (ADCs) greatly benefit breast cancer patients in China. ADCs achieve “precision targeting” of tumors and are referred to as “magic bullets,” changing the … Read more
Antibody-drug conjugates (ADC) are a new class of targeted drugs composed of monoclonal antibodies (mAbs), cytotoxic drugs, and linkers that connect the two. They utilize the targeting capability of antibodies to selectively deliver cytotoxic molecules to tumor cells, exerting anti-cancer effects while avoiding impacts on healthy cells. ADC drugs have rapidly developed in the field … Read more
* For reference by medical professionals only What Issues Should Be Addressed During the Infusion of ADC Drugs for Breast Cancer? ADC drugs combine the precise targeting of antibody drugs with the efficient killing advantage of cytotoxic drugs, gradually changing the treatment landscape for breast cancer. Currently, ADC drugs that have entered clinical practice in … Read more
Breast cancer is the leading cause of death among women in China and worldwide. When breast cancer spreads to other parts of the body, the prognosis is poor. Currently, there is no treatment for metastatic breast cancer. Antibody-drug conjugates (ADCs) are a new type of anticancer drug consisting of antibodies, linkers, and cytotoxic agents [1]. … Read more
Let’s take a moment to focus on the recent hot topic of Antibody–Drug Conjugates and systematically learn about the review published in Cancers: Antibody–Drug Conjugates for the Treatment of Breast Cancer. Abstract Currently, aside from endocrine therapy and targeted drugs, the common treatment method for metastatic breast cancer (BC) is chemotherapy. However, the lack of … Read more
[Image]The 2025 European Society for Medical Oncology (ESMO 2025) Annual Meeting will be held from October 17 to 21 in Berlin, Germany. With the continuous development of precision medicine and personalized treatment, Antibody-Drug Conjugates (ADC) continue to be a significant focus of this conference. Currently, the ESMO official website has announced some oral presentation and … Read more